Fellowship · La Jolla, CA
Sponsored by University of California (San Diego) Medical Center
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
The New England journal of medicine · 2023 · 633 citations · Ramez Eskander
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
The New England journal of medicine · 2022 · 797 citations · David Miller
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 587 citations · Michael McHale, David Miller
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 346 citations · Michael McHale, David Miller
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
JAMA oncology · 2023 · 202 citations · Ramez Eskander
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 127 citations ·
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 117 citations · Ramez Eskander
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Nature medicine · 2025 · 59 citations · Ramez Eskander